Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase

Current Medical Research and Opinion

Volumn 30, Issue 11, 2014, Pages 2317-2328

  Guérin, Annie ^a   Chen, Lei ^b   Ionescu Ittu, Raluca ^a   Marynchenko, Maryna ^c   Nitulescu, Roy ^a   Hiscock, Robert ^a   Keir, Christopher ^b   Wu, Eric Qiong ^c  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ANALYSIS GROUP   (United States)

Author keywords

Adverse effects; Imatinib; Myelogenous leukemia, chronic; Nilotinib; Quality of life

Indexed keywords

HYDROXYUREA; IMATINIB; NILOTINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; COMPARATIVE STUDY; DIARRHEA; FATIGUE; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HEALTH SURVEY; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; NAUSEA; NEUTROPENIA; OBESITY; PERIPHERAL EDEMA; PHILADELPHIA CHROMOSOME POSITIVE CELL; QUALITY OF LIFE; SHORT FORM 36; THROMBOCYTOPENIA; AGED; CLINICAL TRIAL; CONTROLLED STUDY; GENETICS; HEALTH STATUS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MULTICENTER STUDY; PHILADELPHIA 1 CHROMOSOME; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; FEMALE; HEALTH STATUS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PIPERAZINES; PYRIMIDINES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84908610333     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.944973     Document Type: Article

References (42)

1. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7
2. Kantarjian H, OBrien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119:1981-7
3. Baran Y, Saydam G. Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia. J Blood Med 2012;3:139-50
4. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-84
5. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014;123:1353-60
6. Beaumont JL, Magestro M, Coombs J, et al. Assessment of patient reported outcomes (PROs) from the ENESTnd trial with minimum follow-up of 36 cycles. In: 54th ASH Annual Meeting and Exposition. Atlanta, GA: American Society of Hematology, 2012:abstract 3166
7. Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-Term therapy with imatinib compared with the general population. Blood 2011;118:4554-60
8. Ferdinand R, Mitchell SA, Batson S, Tumur I. Treatments for chronic myeloid leukemia: a qualitative systematic review. J Blood Med 2012;3:51-76
9. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26: 2197-203
10. Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) Capsules. Washington, DC: US Food and Drug Administration, 2007:1-21. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/022068lbl. pdf [Last accessed 4 September 2013
11. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia v4.2013. 2013:1-95. Available at: http://www.nccn.org/professionals/physician-gls/pdf/cml.pdf [Last accessed 6 June 2013
12. Lorimer S, Cox A, Langford NJ. A patients perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther 2012;37:148-52
13. Jabbour EJ, Kantarjian H, Eliasson L, et al. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 2012;87:687-91
14. Cortes JE, Lipton JH, Miller CB, et al. Change in chronic low-grade nonhematologic adverse events (AEs) and quality of life (QoL) in adult patients ( pts) with Philadelphia chromosome-positive (Ph) chronic myeloid leukemia in chronic phase (CML-CP) switched from imatinib (IM) to nilotinib (NIL). Blood 2012;120:abstr 3782
15. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 2012;118:3123-7
16. Novartis Pharmaceuticals. A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP). ClinicalTrials.gov. 2007. Available at: http://clinicaltrial.gov/ct2/show/ NCT00471497?termENESTnd&rank1 [Last accessed 29 January 2014
17. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12:841-51
18. Hochhaus A, Saglio G, Larson RA, et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2013;121:3703-8
19. Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9
20. Cella D, Jensen SE, Webster K, et al. Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy-Leukemia (FACTLeu) questionnaire. Value Health 2012;15:1051-8
21. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Lincoln, Rhode Island: QualityMetric, Inc., 1993
22. Cella D. The manual of the functional assessment of chronic illness therapy (FACIT) measurement system. Evanston, IL: Center on Outcomes, Research, and Education, Evanston Northwestern Healthcare and Northwestern University, 1997
23. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9
24. Trask PC, Cella D, Besson N, et al. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res 2012;36:438-42
25. Ware JE, Kosinski M, Turner-Bowker DM, et al. How to score version 2 of the SF-12 Health Survey (with a supplement documenting version 1). Lincoln, RI: QualityMetric Incorporated, 2002
26. Ware JE. SF-36 health survey update. The use of psychological testing for treatment planning and outcomes assessment 3 2004;693-718
27. MedDRA Maintenance and Support Services, International Federation of Pharmaceutical Manufacturers &Associations (IFPMA). Introductory Guide MedDRA Version 17.0. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2011:1-83. Available at: http://www.meddra.org/sites/default/files/guidance/ file/intguide-17-0-english.pdf [Last accessed 29 January 2014
28. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v3.0. 2013. Available at: http://ctep.cancer.gov/protocol Development/electronic-applications/ctc.htm [Last accessed 19 November 2013
29. Albert PS. Longitudinal data analysis (repeated measures) in clinical trials. Stat Med 1999;18:1707-32
30. Gelman A, Hill J. Data analysis using regression and multilevel/hierarchical models. New York, NY: Cambridge University Press, 2006
31. Bender R, Lange S. Adjusting for multiple testing - when and how?. J Clin Epidemiol 2001;54:343-9
32. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-6
33. Hong H, Qiu J-Y, Lai Y-Y, et al. Analysis of cytogenetic response in Ph+ chronic myeloid leukemia patients treated with interferon alpha. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2003;11:269-73
34. Larson RA. CML: live long and prosper. Blood 2011;118:4499-500
35. Efficace F, Breccia M, Saussele S, et al. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?. GIMEMA and EORTC Quality of Life Group. Ann Hematol 2012;91:1371-81
36. Efficace F, Baccarani M, Breccia M, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 2013;27: 1511-19
37. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010;104:296-304
38. Larson RA, Hochhau A, Saglio G, et al. Nilotinib versus imatinib in patients ( pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP): ENESTnd 4-year (y) update. J Clin Oncol 2013;31(15 Suppl):7052
39. Halyard MY, Ferrans CE. Quality-of-Life assessment for routine oncology clinical practice. J Support Oncol 2008;6:221-9, 233
40. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671-9
41. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) C for BE and R (CBER). Guidance for Industry: Non-Inferiority Clinical Trials - Draft Guidance. Rockville, MD: US Department of Health and Human Services Food and Drug Administration, 2010:1-66. Available at: http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/default.htm [Last accessed 25 April 2014
42. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: E 10 Choice of Control Group and Related Issues in Clinical Trials. Rockville, MD: US Department of Health and Human Services Food and Drug Administration, 2001:1-37. Available at: http://www.fda.gov/cder/guidance/index.htm [Last accessed 25 April 2014